0
0
Read Time:17 Second
A common mRNA COVID-19 vaccine could nearly double survival for advanced lung and skin cancer patients on immunotherapy. Receiving the vaccine within 100 days of starting treatment boosted median survival from about 21 to 37 months! This breakthrough hints at a powerful new ally in cancer care. #CancerResearch #Immunotherapy #VaccineImpact
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
